N-[4-methyl-5-[3-(2-pyridin-2-ylethenyl)-1H-indazol-6-yl]-1,3-thiazol-2-yl]-2-piperidin-3-ylacetamide
C25H26N6OS — CID 166728483
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[4-methyl-5-[3-(2-pyridin-2-ylethenyl)-1H-indazol-6-yl]-1,3-thiazol-2-yl]-2-piperidin-3-ylacetamide
N-[4-methyl-5-[3-(2-pyridin-2-ylethenyl)-1H-indazol-6-yl]-1,3-thiazol-2-yl]-2-piperidin-3-ylacetamide (PubChem CID 166728483) has the molecular formula C25H26N6OS and a molecular weight of 458.59 g/mol. Its IUPAC name is N-[4-methyl-5-[3-(2-pyridin-2-ylethenyl)-1H-indazol-6-yl]-1,3-thiazol-2-yl]-2-piperidin-3-ylacetamide.
Molecular Properties
| Compound Name | N-[4-methyl-5-[3-(2-pyridin-2-ylethenyl)-1H-indazol-6-yl]-1,3-thiazol-2-yl]-2-piperidin-3-ylacetamide |
|---|---|
| PubChem CID | 166728483 |
| Molecular Formula | C25H26N6OS |
| Molecular Weight | 458.59 g/mol |
| Exact Mass | 458.19 |
| IUPAC Name | N-[4-methyl-5-[3-(2-pyridin-2-ylethenyl)-1H-indazol-6-yl]-1,3-thiazol-2-yl]-2-piperidin-3-ylacetamide |
| SMILES | Cc1nc(NC(=O)CC2CCCNC2)sc1-c1ccc2c(C=Cc3ccccn3)n[nH]c2c1 |
| InChI | InChI=1S/C25H26N6OS/c1-16-24(33-25(28-16)29-23(32)13-17-5-4-11-26-15-17)18-7-9-20-21(30-31-22(20)14-18)10-8-19-6-2-3-12-27-19/h2-3,6-10,12,14,17,26H,4-5,11,13,15H2,1H3,(H,30,31)(H,28,29,32) |
| InChIKey | XIGBNXDFPWNTCP-UHFFFAOYSA-N |
| XLogP | 4.89 |
| TPSA | 95.59 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 458.59 |
| LogP ≤ 5 | 4.89 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 166728483 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.